Rankings
▼
Calendar
DAWN Q3 2025 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
DAWN
Day One Biopharmaceuticals, Inc.
$2B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$40M
-57.6% YoY
Gross Profit
$35M
88.7% margin
Operating Income
-$24M
-60.9% margin
Net Income
-$20M
-49.6% margin
EPS (Diluted)
$-0.19
QoQ Revenue Growth
+17.4%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$6M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$514M
Total Liabilities
$63M
Stockholders' Equity
$451M
Cash & Equivalents
$43M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$40M
$94M
-57.6%
Gross Profit
$35M
$92M
-61.7%
Operating Income
-$24M
$30M
-181.8%
Net Income
-$20M
$37M
-153.3%
Revenue Segments
Product
$39M
97%
License
$1M
3%
← FY 2025
All Quarters
Q4 2025 →